drugset / Trial / NCT00858858

Clinical Studies on Bile Acids in Barrett's Esophagus

NCT00858858

Completed 60 enrolled US Department of Veterans Affairs
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux disease (GERD) 2. To determine whether changes in bile composition induced by treating patients with a bile salt called ursodeoxycholic acid (UDCA) can alter DNA injury, signaling pathway activation and other types of damage in cells from the esophagus of patients who have GERD.

Timeline

Start
2009-03
Primary completion
2013-03
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 10 mg/kg Oral